At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 30 enrolled
Drug / intervention
Mirabegron +1 moredrug
Likely dose
Mirabegron 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease. (MAESTRO)
In Brief
A Phase 4 clinical trial evaluating Mirabegron and Placebo for Parkinsons Disease. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The purpose of this study is to see if the study drug, Mirabegron, is safe and effective in treating symptoms of Overactive Bladder in people with Parkinson's Disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinsons Disease
CountriesUnited States
CollaboratorsAstellas Pharma US, Inc.
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMar 2014
First PostedMar 2014
Primary CompletionJul 2018
TodayJul 2026
First PostedMar 20, 2014
Enrollment StartMar 1, 2014
Primary CompletionJul 1, 2018
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 12.3 years ago
Interventions
Mirabegrondrug
25 mg po daily for 32-40 days. Following up-titration to 50 mg po daily. This is pending no adverse events on the 25 mg dose.
Placebodrug
Placebo 25 mg po daily. Following up-titration to 50 mg po daily. This is pending no adverse events on the 25 mg dose.